Argenx Expands VYVGART's Horizon with Key New Data in Neurology
The biopharmaceutical group argenx announces the presentation of new clinical data for VYVGART and its drug candidates at the annual American Academy of Neurology (AAN) congress taking place in Chicago from April 18 to 22, 2026. The data focus on the expansion of VYVGART's use in severe myasthenia and chronic inflammatory demyelinating polyneuropathy (CIDP), as well as progress in other muscular neurology research programs.
Expanding Access to VYVGART
Argenx presents clinical data supporting the expansion of access to VYVGART beyond its currently approved indication. The company is making progress towards its goal of extending VYVGART's reach to as many patients with severe myasthenia as possible, regardless of subtype. The new data includes results from the ADAPT OCULUS study, evaluating VYVGART in subcutaneous injection for patients with ocular myasthenia, as well as results from the ADAPT SERON study on patients seronegative for anti-AChR antibodies.
Advancing Beyond VYVGART
Beyond VYVGART, argenx is advancing multiple therapeutic programs. Data related to VYVGART Hytrulo highlight its potential to produce early clinical improvement in patients with CIDP being treated for the first time. The company is also evaluating empasiprubart in phase 3 studies for the treatment of CIDP, and presents new data for adimanebart in congenital myasthenic syndromes.
